Clinician-founders do not win by proving everything at once. They win by sequencing evidence, reimbursement and distribution around the buyer’s real constraints.
AI-native devices do not just add software margin to medtech; they shift costs, risk, reimbursement, and defensibility toward the recurring act of clinical inference.
The winning order is not always build, publish, sell. Clinician-founders need to align proof, payment and distribution around the same economic decision-maker.
